Lifeloc Q2 2024 net loss of $298K; rev $2.387M (+5% YoY); SpinDx beta in 2024

Lifeloc Technologies, Inc

2024-Q2 EPS reported -$0.24 revenue$4,540,773

Net loss $(298K) ($0.12/diluted) vs net income $55K ($0.02) in Q2 2023.
Revenue increased 5% to $2.387M; gross margin fell to 41.6% from 45.7%.
R&D spending rose 67% to $662K, primarily for SpinDx saliva THC detection.
Cash at $505K; post-quarter closed $750K credit line + $798K private placement.
SpinDx beta testing planned H2 2024; commercial launch targeted for 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.